Clinical trials: Tirzepatide
Psoriasis, Overweight or Obesity
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1…
- Trial name
- NCT06857942
- Testing
- Tirzepatide
- Where
- 38 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Obesity
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin.
- Trial name
- NCT06037252
- Testing
- Tirzepatide
- Where
- 40 sites in United States, Argentina and 2 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes.
- Trial name
- NCT06901349
- Testing
- Bimagrumab, Tirzepatide
- Where
- 50 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Obesity
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
- Trial name
- TRIUMPH-5 (NCT06662383)
- Testing
- Retatrutide, Tirzepatide
- Where
- 65 sites in United States, Argentina and 3 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Hypoglycemia
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes.
- Trial name
- NCT04050553
- Testing
- Tirzepatide
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1.
- Trial name
- NCT07262762
- Where
- 14 sites in Iran
- Volunteers
- 175 people
- Sponsor
- Cinnagen
Obesity &Amp; Overweight
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161…
- Trial name
- NCT07245771
- Testing
- RN3161, Tirzepatide
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
- Trial name
- NCT03311724
- Testing
- Tirzepatide
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
- Trial name
- SURPASS J-mono (NCT03861052)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 46 sites in Japan
- Volunteers
- 636 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight.
- Trial name
- NCT06297616
- Testing
- LY3841136, Tirzepatide
- Where
- 3 sites in Japan
- Volunteers
- 128 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Trial name
- NCT07803744
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a…
- Trial name
- NCT03951753
- Testing
- Tirzepatide, Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or…
- Conditions
- Obesity, Overweight, Overweight With One Weight Related Comorbidity
- Trial name
- GYMINDA (NCT06965413)
- Testing
- RO7204239, Tirzepatide
- Where
- 35 sites in United States, Poland and 2 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche